TIAN RUIXIANG Holdings Ltd Completes Acquisition of Ucare Inc., Marking Strategic Expansion into AI-Powered Health Insurance Solutions
TIAN RUIXIANG Holdings (NASDAQ:TIRX) has completed the acquisition of Ucare Inc. in an all-stock transaction valued at $150 million. The deal involves issuing 101,486,575 Class A ordinary shares at $0.025 par value per share.
Ucare operates China's only cloud-based AI-driven hospital and health insurance risk management platform, serving over 4,000 hospitals. The acquisition strategically positions TRX at the intersection of healthcare and insurance, with plans to integrate Ucare's generative AI technology into TRX's health insurance workflows for improved fraud detection, operational efficiency, and pricing accuracy.
The merger aims to create an integrated insurance-hospital ecosystem, with Ucare leveraging TRX's platform, capital resources, and strategic relationships to advance R&D and expand its AI capabilities. The combined entity will focus on developing innovative healthcare solutions and expanding business channels while enhancing transparency and efficiency in health insurance services.
TIAN RUIXIANG Holdings (NASDAQ:TIRX) ha completato l'acquisizione di Ucare Inc. tramite un'operazione completamente in azioni del valore di 150 milioni di dollari. L'accordo prevede l'emissione di 101.486.575 azioni ordinarie di Classe A con un valore nominale di 0,025 dollari per azione.
Ucare gestisce l'unica piattaforma cinese basata su cloud con intelligenza artificiale per la gestione del rischio negli ospedali e nelle assicurazioni sanitarie, servendo oltre 4.000 ospedali. L'acquisizione posiziona strategicamente TRX all'incrocio tra assistenza sanitaria e assicurazioni, con l'intenzione di integrare la tecnologia di intelligenza artificiale generativa di Ucare nei processi assicurativi sanitari di TRX per migliorare il rilevamento delle frodi, l'efficienza operativa e la precisione nella definizione dei prezzi.
La fusione mira a creare un ecosistema integrato tra assicurazioni e ospedali, con Ucare che sfrutterà la piattaforma, le risorse finanziarie e le relazioni strategiche di TRX per potenziare la ricerca e sviluppo e ampliare le sue capacità di intelligenza artificiale. L'entità combinata si concentrerà sullo sviluppo di soluzioni sanitarie innovative e sull'espansione dei canali commerciali, migliorando al contempo trasparenza ed efficienza nei servizi di assicurazione sanitaria.
TIAN RUIXIANG Holdings (NASDAQ:TIRX) ha completado la adquisición de Ucare Inc. mediante una transacción totalmente en acciones valorada en 150 millones de dólares. El acuerdo implica la emisión de 101,486,575 acciones ordinarias Clase A con un valor nominal de 0,025 dólares por acción.
Ucare opera la única plataforma china basada en la nube impulsada por IA para la gestión de riesgos hospitalarios y de seguros de salud, atendiendo a más de 4,000 hospitales. La adquisición posiciona estratégicamente a TRX en la intersección de la salud y los seguros, con planes para integrar la tecnología de IA generativa de Ucare en los flujos de trabajo de seguros de salud de TRX para mejorar la detección de fraudes, la eficiencia operativa y la precisión en la fijación de precios.
La fusión busca crear un ecosistema integrado de seguros y hospitales, donde Ucare aprovechará la plataforma, los recursos de capital y las relaciones estratégicas de TRX para avanzar en I+D y expandir sus capacidades de IA. La entidad combinada se enfocará en desarrollar soluciones innovadoras en salud y en ampliar los canales comerciales, mejorando al mismo tiempo la transparencia y eficiencia en los servicios de seguros de salud.
TIAN RUIXIANG Holdings (NASDAQ:TIRX)는 Ucare Inc.를 총 1억 5천만 달러 상당의 전액 주식 거래로 인수 완료했습니다. 이번 거래는 액면가 0.025달러인 클래스 A 보통주 101,486,575주를 발행하는 방식으로 진행되었습니다.
Ucare는 4,000개 이상의 병원을 대상으로 중국 유일의 클라우드 기반 AI 병원 및 건강 보험 리스크 관리 플랫폼을 운영하고 있습니다. 이번 인수로 TRX는 헬스케어와 보험의 교차점에 전략적으로 자리매김하며, Ucare의 생성형 AI 기술을 TRX의 건강 보험 업무에 통합해 사기 탐지, 운영 효율성, 가격 정확성을 향상시킬 계획입니다.
이번 합병은 보험과 병원을 통합한 생태계 조성을 목표로 하며, Ucare는 TRX의 플랫폼, 자본 자원 및 전략적 관계를 활용해 연구개발을 촉진하고 AI 역량을 확장할 예정입니다. 통합 법인은 혁신적인 헬스케어 솔루션 개발과 사업 채널 확장에 주력하며, 건강 보험 서비스의 투명성과 효율성을 높일 것입니다.
TIAN RUIXIANG Holdings (NASDAQ:TIRX) a finalisé l'acquisition de Ucare Inc. dans le cadre d'une transaction entièrement en actions d'une valeur de 150 millions de dollars. L'accord prévoit l'émission de 101 486 575 actions ordinaires de classe A d'une valeur nominale de 0,025 dollar par action.
Ucare exploite la seule plateforme chinoise basée sur le cloud, pilotée par l'IA, pour la gestion des risques hospitaliers et de l'assurance santé, desservant plus de 4 000 hôpitaux. Cette acquisition positionne stratégiquement TRX à l'intersection des secteurs de la santé et de l'assurance, avec l'intention d'intégrer la technologie d'IA générative d'Ucare dans les flux de travail d'assurance santé de TRX afin d'améliorer la détection des fraudes, l'efficacité opérationnelle et la précision des tarifications.
La fusion vise à créer un écosystème intégré assurance-hôpital, Ucare tirant parti de la plateforme, des ressources financières et des relations stratégiques de TRX pour faire progresser la R&D et étendre ses capacités en IA. L'entité combinée se concentrera sur le développement de solutions innovantes en santé et l'expansion des canaux commerciaux tout en améliorant la transparence et l'efficacité des services d'assurance santé.
TIAN RUIXIANG Holdings (NASDAQ:TIRX) hat die Übernahme von Ucare Inc. in einer vollständig aktienbasierten Transaktion im Wert von 150 Millionen US-Dollar abgeschlossen. Die Vereinbarung umfasst die Ausgabe von 101.486.575 Stammaktien der Klasse A mit einem Nennwert von 0,025 US-Dollar pro Aktie.
Ucare betreibt Chinas einzige cloudbasierte, KI-gesteuerte Plattform für Krankenhaus- und Krankenversicherungsrisikomanagement und betreut über 4.000 Krankenhäuser. Die Übernahme positioniert TRX strategisch an der Schnittstelle von Gesundheitswesen und Versicherung, mit Plänen, Ucares generative KI-Technologie in TRXs Krankenversicherungsprozesse zu integrieren, um Betrugserkennung, operative Effizienz und Preisgenauigkeit zu verbessern.
Die Fusion zielt darauf ab, ein integriertes Versicherungs-Krankenhaus-Ökosystem zu schaffen, wobei Ucare TRXs Plattform, Kapitalressourcen und strategische Partnerschaften nutzt, um Forschung und Entwicklung voranzutreiben und seine KI-Fähigkeiten auszubauen. Das kombinierte Unternehmen wird sich auf die Entwicklung innovativer Gesundheitslösungen und die Erweiterung von Vertriebskanälen konzentrieren und dabei Transparenz und Effizienz in der Krankenversicherung verbessern.
- Strategic acquisition valued at $150 million positions TRX in the growing health insurance sector
- Access to Ucare's network of over 4,000 hospitals expands distribution channels
- Integration of advanced generative AI technology expected to reduce fraud and improve operational efficiency
- Creation of unique health insurance offerings through combined capabilities
- Enhanced R&D capabilities and expanded market reach through merger synergies
- Significant share dilution due to issuance of 101,486,575 new Class A ordinary shares
- Integration risks associated with merging two different technology platforms
- Execution challenges in creating seamless insurance-hospital ecosystem
Insights
TIRX's $150M acquisition of Ucare brings AI capabilities to health insurance, potentially transforming its business model and growth trajectory.
TIAN RUIXIANG Holdings has completed a significant
The strategic rationale centers on Ucare's unique position as the sole operator of China's cloud-based AI hospital and health insurance risk management platform. This acquisition gives TIRX immediate access to Ucare's relationships with over 4,000 hospitals and its proprietary AI analytics capabilities. For investors, this represents both opportunity and execution risk as TIRX attempts to leverage these assets into new revenue streams.
The integration strategy focuses on embedding Ucare's generative AI capabilities into TIRX's underwriting and claims processing workflows. This has potential to create operational efficiencies through reduced fraud, streamlined operations, and improved pricing precision. However, investors should note this represents a significant business model evolution that will require successful technology integration and adoption by healthcare providers and insurance partners to realize its full value.
This acquisition positions TIRX at the intersection of two high-growth sectors in China: healthcare technology and insurance services. The ability to create data-driven insights from hospital relationships could potentially transform how health insurance products are designed and distributed, though successful execution will be crucial to realizing this potential.
BEIJING, June 30, 2025 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the “Company” or “TRX”), a China-based insurance broker, today announced it has completed the acquisition of
As part of the closing, TRX has issued 101,486,575 Class A ordinary shares, each with a par value of US
Leveraging Ucare’s existing relationships with over 4,000 hospitals and leading AI analytics, TRX will expand business channels and build unique health insurance service offerings. Ucare’s generative AI platform will be integrated into TRX’s underwriting and claims processing health insurance workflows to reduce fraud, streamline operations, and improve pricing precision.
Ms. Sheng Xu, Director, Chairwoman and Chief Executive Officer of TRX, stated, “We are thrilled to officially welcome Ucare to the TRX family. This acquisition places us at the intersection of healthcare and insurance, unlocking data-driven insights that will transform how health insurance is designed, sold, and serviced. In the coming months, we are focused on expediting Ucare’s growth by building on the success it’s already achieved, while designing differentiated offerings that align with evolving patient needs and national healthcare priorities. Our long-term goal is to create a seamless insurance-hospital ecosystem that enhances transparency, efficiency, and accessibility for all stakeholders.”
Mr. Wei Zhu, Chief Executive Officer of Ucare, added, “Joining TRX opens an exciting new chapter for Ucare’s mission to reshape hospital and health insurance risk management in China. With TRX’s resources, we are well-positioned to accelerate our platform deployment and deepen integration with insurance services. Together, we will lead the next wave of innovation in medical cost containment and health insurance.”
About TIAN RUIXIANG Holdings Ltd
TIAN RUIXIANG Holdings Ltd, headquartered in Beijing, China, is an insurance broker operating in China through its China-based variable interest entity. It distributes a wide range of insurance products, which are categorized into two major groups: (1) property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and (2) other types of insurance, such as health insurance, life insurance, and other miscellaneous insurance.
About Ucare Inc.
Ucare Inc. develops innovative healthcare solutions that enable providers, payers, and institutions to reduce fraud, abuse, waste, and administrative costs. Powered by the largest hospital database, Ucare's cloud-based generative AI platform continuously refines disease models by integrating real-world data, the latest medical guidelines, and real-time intelligence. Ucare's vision is to ease the burden on patients, expand coverage, and ultimately improve access to healthcare for everyone.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review risk factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.
For investor and media enquiries, please contact:
TIAN RUIXIANG Holdings Ltd
Investor Relations Department
Email: ir@tianrx.com
Water Tower Research
Feifei Shen
Email: feifei@watertowerresearch.com
FAQ
What is the value of TIRX's acquisition of Ucare Inc.?
How many hospitals are currently in Ucare's network?
What technology does Ucare bring to TIRX's operations?
How will the Ucare acquisition benefit TIRX's business?
What are TIRX's plans for Ucare post-acquisition?
